Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)

Exclusion Criteria

• •1. Any prior therapy used for treatment of CLL or SLL
• •2. History of other malignancies, except in situ carcinoma or malignancy treated with curative intent
• •3. Known or suspected history of Richter's transformation
• •4. Known hypersensitivity to one or more study drugs
• •5. Inadequate renal function: CrCl \<30 mL/min
• •6. Uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia
• •7. Requires the use of warfarin or derivatives
• •8. Treatment with any of the following within 7 days prior to the first dose of study drug:
• •1. Steroid therapy for anti-neoplastic intent
• •2. Moderate or strong cytochrome P450 3A (CYP3A) inhibitors (see Appendix G for examples)
• •3. Moderate or strong CYP3A inducers (see Appendix G for examples)